{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:08:25Z","timestamp":1698667705493},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,9,10]],"date-time":"2007-09-10T00:00:00Z","timestamp":1189382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> We recently developed and validated limited sampling models (LSMs) for cyclosporine monitoring after orthotopic liver transplantation based on individualized population pharmacokinetic models with Bayesian modelling.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To evaluate LSM in practice, and to seek optimal balance between benefit and discomfort.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In 30 stable patients, more than 6\u2003months after orthotopic liver transplantation, previously switched from trough\u2010 to 2\u2003h post\u2010dose (C2)\u2010monitoring, we switched to 3\u2010monthly LSM 0,1,2,3\u2003h\u2010monitoring. During 18\u2003months we evaluated dose, creatinine clearance, calculated area under the curve, intra\u2010patient pharmacokinetic variability and ability to assess systemic exposure by several previously validated LSMs.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Within patients, there was variability of cyclosporine\u2010area under the curve with the same dose (CV of 15%). Compared to C2\u2010monitoring, there was no significant difference in dose (<jats:italic>P<\/jats:italic>\u2003=\u20030.237), creatinine clearance (<jats:italic>P<\/jats:italic>\u2003=\u20030.071) and number of rejections. Some models showed excellent correlation and precision with LSM 0,1,2,3\u2003h comparing area under the curves (0,2\u2003h: r<jats:sup>2<\/jats:sup>\u2003=\u20030.88; 0,1,3\u2003h: r<jats:sup>2<\/jats:sup>\u2003=\u20030.91; 0,2,3\u2003h: r<jats:sup>2<\/jats:sup>\u2003=\u20030.92, all <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) with no difference in advised dose.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The limited sampling model, with only trough\u2010 and 2\u2010h sampling, yields excellent accuracy and assesses systemic exposure much better than C2 with less bias and greater precision. Considering the calculated intra\u2010patient variability, more precision is redundant, so LSM 0,2\u2003h seems the optimal way of cyclosporine\u2010monitoring.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2007.03514.x","type":"journal-article","created":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T18:44:57Z","timestamp":1223923497000},"page":"1447-1454","source":"Crossref","is-referenced-by-count":7,"title":["Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice"],"prefix":"10.1111","volume":"26","author":[{"given":"P.","family":"LANGERS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. C. L. M.","family":"CREMERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"DEN HARTIGH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M. T.","family":"RIJNBEEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"RINGERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. B. H. W.","family":"LAMERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"HOMMES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"VAN HOEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,10]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"279","article-title":"C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation","volume":"15","author":"Levy GA","year":"2001","journal-title":"Bio Drugs"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205151-00002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.08.008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205151-00004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199812270-00009"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904270-00008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02317-X"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)02318-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(02)03009-9"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200203270-00022"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20056"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02364.x"},{"key":"e_1_2_6_14_2","first-page":"531","article-title":"Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting","volume":"33","author":"Proost JH","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060893"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.01.054"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000243965.97964.ca"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200104000-00003"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03514.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03514.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:04:07Z","timestamp":1697421847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03514.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03514.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03514.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,10]]}}}